← Back

Yunnan Hongxiang Yixintang

Yixintang Pharmaceutical Group Co., Ltd. operates a pharmaceutical retail chain and distribution business with its subsidiary. It engages in the wholesale and retail of medical devices, food, disinfectants, cosmetics, and daily necessities, as well as manufacturing glasses and providing telecommunications, internet live broadcast, and health services. The company also offers clinic and foot bath services, operates aquatic wild animals and a call center, retails publications, and provides decoction services for Chinese herbal medicines. It was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Founded in 2000, it is headquartered in Kunming, China.

Price · split & dividend adjusted
News & notes moving 002727.CS
002727.CS▼2

Yixintang's 2026 interim report shows net profit of 257 million yuan

Yixintang released its 2026 interim report. Total operating revenue was 8.467 billion yuan, down 5.02% from the same period last year, and net profit attributable to the parent company was 257 million yuan. Net cash inflow from operating activities was 1.249 billion yuan, the asset-liability ratio was 50.30%, gross margin was 33.23%, and diluted earnings per share was 0.45 yuan. The number of shareholders was 39,500, and the top ten shareholders held 55.00% of total share capital.
002727.CS ▼
Jiemian·23dRead more →
002727.CS

Yixintang's first-half net profit attributable to parent was 257 million yuan, up 2.9% year on year

Yixintang released its 2026 interim report. First-half net profit attributable to the parent was 257 million yuan, up 2.9% year on year, while operating revenue was 8.47 billion yuan, down 5.0% year on year. Second-quarter net profit attributable to the parent was 81.04 million yuan, down 9.5% year on year. The company's operational focus has shifted from scale expansion to optimizing existing assets and improving quality and efficiency. It is implementing five strategic pillars including store adjustments and category innovation, with the sales share of non-pharmaceutical categories rising 11.8% year on year. As of the end of the second quarter, total assets were 15.308 billion yuan and net assets attributable to the parent were 7.446 billion yuan.
002727.CS
财中社·24dRead more →
© 2026 MarketDXAsset